Risk of Unachieved Synergies and Impairment of Investment Value in Acquisitions
First written in FY2019-Q3. 3 of 6 entries say "Restated". Latest entry: FY2023-Q3.
The whole theme swung hardest in 2024: 36 of 89 companies on the "Worse" side.
- FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
The Company has disclosed that there have been no material changes to the risk of unrealised synergies and impairment of investment value in acquisitions. - FY2021-Q2RestatedAnnual report
「If the business does not progress as initially planned, or if the expected benefits are not realised because of significant changes in the business environment or competitive landscape, the Group's operating performance and financial position could be affected, including by the need to impair investment value.」
The Company continues to disclose the risks of failing to achieve planned targets, failing to realise expected benefits and impairing investment value in connection with business reorganisations, including the establishment and sale of affiliates, due to changes in the business environment. - FY2020MaterialisedAnnual report
「After considering future uncertainties when preparing the business plans of both companies, we recognised the full carrying amount of the goodwill arising at both companies as an impairment loss.」
The full carrying amount of goodwill arising from the acquisitions of Cell Technology and Japan Regenerative Medicine was recognised as an impairment loss because of future uncertainties. - FY2020-Q1MaterialisedAnnual report
「The entire amount was recognised as an impairment loss during the first quarter of the current consolidated fiscal year.」
The entire ¥5,938.083 million of goodwill arising from the acquisition of Cell Technology was recognised as an impairment loss during the first quarter of the current consolidated fiscal year. The risk of impairment of investment value following an acquisition has materialised. - FY2019RestatedAnnual report
「The expected synergies may not be realised because of inadequate due diligence on the target company or significant changes in the business environment or competitive landscape. In such cases, the investment value of the target company may need to be impaired, which could affect the Company's business plans and operating performance.」
The Company continues to disclose the risk of unrealised synergies and impairment of investment value following acquisitions. - FY2019-Q3First statedAnnual report
「The Company may conduct acquisitions and other transactions as a means of expanding its business. However, the expected synergies may not be realised because of inadequate due diligence on the target company or significant changes in the business environment or competitive landscape. In such cases, the investment value of the target company may need to be impaired, which could affect the Company's business plans and operating performance.」
While using acquisitions as a means of business expansion, the Company has disclosed as a new risk the possibility that expected synergies may not be realised because of inadequate due diligence or changes in the business environment, resulting in impairment of investment value.